In the Pipeline

Our pipeline is focused on research in therapeutic areas where we believe we have the best opportunity to deliver transformational medicines to patients.

Our Pipeline at a Glance

As of Feb 06, 2022

50+
Compounds in Development

40+
Diseases Where Being Studied

Use any other scientific evidence, clinical trial data or drug compounds in a complete, time-consuming, resource-intensive process with no guaranteed results. But, as described here, Bristol Myers Squibb is committed to pursuing such clinical development and is doing so. In bringing new hope to patients.

In the Pipeline

Download Pipeline

Filter

Therapeutic Area Phase

All Therapeutic Areas

The safety and efficacy of investigational agents within investigational phase of approved products have not been established.

Therapeutic Compound	Patient Population/ Line of Therapy	Phase 1	Phase 2	Phase 3
Hematology
Sickle Cancer				
cetuximab-mutetravir + ifosfamide	Solid Tumors			
ORIGIMED™ & BRISTOL-MYERS SQUIBB CELGENE	Solid Tumors			
	Solid Tumors			
	Solid Tumors			
ORIGIMED™ & CELGENE	Colorectal, 2nd line			
	Non Tumor Tells Sigh			
	Pediatrics			
	Solid Tumors			
	Solid Tumors			
ORIGIMED™ & CELGENE **mutetravir**	Solid Tumors			
ORIGIMED™ & CELGENE **mutetravir**	Solid Tumors			
anti-CTLA-4 MT	Solid Tumors			
anti-CTLA-4 Probody®	Solid Tumors			
MT Cetuximab (CC-90019)™	Solid Tumors			
anti-Pyroxyl GH1	Solid Tumors			
selinexor •	Solid Tumors			
TIGIT Biparatope (Agenus)	Solid Tumors			
Telmelumumab-mitvin ADC •	Solid Tumors			
	Solid Tumors			
Anti-TIGIT	Solid Tumors			
Anti-TIM-3	Solid Tumors			
STING Agonist	Solid Tumors			
Anti-DDR1a	Solid Tumors			
CD16/PD-L1 Bispecific (GSK668)	Solid Tumors			
Anti-IL-8	Solid Tumors			
JAK Antagonist (Taiwo)	Solid Tumors			
Anti-CTLA-4 MT Probody®	Solid Tumors			
MT Cetuximab (CC-90019)™	Solid Tumors			
HK-LDD	Solid Tumors			
Anti-MRGPR	Solid Tumors			
TAFR Cetuximab	Solid Tumors			
IL-15 Hi	Solid Tumors			
Anti-CCR8	Solid Tumors			
MAGE-A4 TCE •	Solid Tumors			
Lung				
ORIGIMED™ & CELGENE	Neoadjuvant NSCLC			
	Unresectable NSCLC			
	Pre-adjuvant NSCLC			
ORIGIMED™ & CELGENE & BRISTOL-MYERS SQUIBB CELGENE	NSCLC EGFR Mutant			
	Unresectable NSCLC			
LSD1 Cetuximab	Extensive Stage SCLC			
Head & Neck				
ORIGIMED™ & CELGENE	Locally Advanced 1st line			
mutetravir	SCCHN			
Gastrointestinal Cancers (GI)				
ORIGIMED™ & CELGENE	Esophagus 1st line			
ORIGIMED™ & CELGENE & BRISTOL-MYERS SQUIBB CELGENE	Esophagus 1st line			
Genitourinary				
ORIGIMED™ & CELGENE	1st line			
PSMA/CD3™ Bispecific(GSK)	Pediatrics			
Hepatocellular Carcinoma (HCC)				
ORIGIMED™ & CELGENE	Adjuvant			
	1st line			
ORIGIMED™ & CELGENE & BRISTOL-MYERS SQUIBB CELGENE	Unresectable			
	1st line			
Breast				
ORIGIMED™ & CELGENE & BRISTOL-MYERS SQUIBB CELGENE	1st line			
ORIGIMED™ & CELGENE	High Risk Non-Muscle Invasive			
ORIGIMED™ & CELGENE	Neoadjuvant Muscle Invasive			
ORIGIMED™ & CELGENE & Vertalogdelimotin-c	Muscle Invasive			
	1st line			
Prostate Cancer (PC)				
selinexor-mutetravir + ifosfamide	Advanced			
ORIGIMED™ & CELGENE	Adjuvant			
ORIGIMED™ & CELGENE & BRISTOL-MYERS SQUIBB CELGENE	Adjuvant			
ORIGIMED™ & CELGENE & Vertalogdelimotin-c	1st line			
ORIGIMED™ & CELGENE & BRISTOL-MYERS SQUIBB CELGENE & selinexor•	Metastatic			
Kidney				
ORIGIMED™ & CELGENE	Adjuvant			
ORIGIMED™ & CELGENE & BRISTOL-MYERS SQUIBB CELGENE	1st line			
Bladder				
ORIGIMED™ & CELGENE & BRISTOL-MYERS SQUIBB CELGENE	Adjuvant			
ORIGIMED™ & CELGENE **selinexor**	1st line			
ORIGIMED™ & CELGENE & Vertalogdelimotin-c	1st line			
ORIGIMED™ & CELGENE & Vertalogdelimotin-c	Adjuvant			
ORIGIMED™ & CELGENE	Adjuvant			
Cholangiocarcinoma (CCA)				
ORIGIMED™ & CELGENE & BRISTOL-MYERS SQUIBB CELGENE	CRC MSI High 1st line			
Ovarian				
ORIGIMED™ & CELGENE	Metastatic Carcinoma Resistant			
ORIGIMED™ & CELGENE & BRISTOL-MYERS SQUIBB CELGENE	Metastatic Carcinoma Resistant			
Uterine				
ORIGIMED™ & CELGENE	Neoadjuvant (N=HRS)			
ORIGIMED™ & CELGENE & BRISTOL-MYERS SQUIBB CELGENE	Neoadjuvant (N=HRS)			
Hematology
Myelodysplastic Syndrome (MDS)				
ORIGIMED CELGENE™	Relapsed/Refractory 1st line			
	Relapsed/Refractory 2nd line			
	Relapsed/Refractory 3rd line			
	High risk Newly Diagnosed Multiple Myeloma			
BMS2020™ & ORIGIMED™ & BRISTOL-MYERS SQUIBB CELGENE	1st line			
ORIGIMED™ & BMS2020™ & BRISTOL-MYERS SQUIBB CELGENE	Relapsed/Refractory			
Iberdomide	Relapsed/Refractory			
ROSA-ADC	Relapsed/Refractory			
anti-DLL4/anti-VEGF/ROBO	Relapsed/Refractory			
ROSA-TCE	Relapsed/Refractory			
ROSA-NKT	Relapsed/Refractory			
OPN/CD3 CAR-T	Relapsed/Refractory			
CD10-NKE	Relapsed/Refractory			
ROSA-NKE	Relapsed/Refractory			
Myeloproliferative Neoplasms (MPN)				
selinexor •	Hematologic Malignancies			
ORIGIMED™ & CELGENE	Hematologic Malignancies			
MT Cetuximab (CC-90019)™	Hematologic Malignancies			
MT Cetuximab (BMS-986158)™	Hematologic Malignancies			
CD-to Degrasyn	Hematologic Malignancies			
NUH-1 Cell-T	Hematologic Malignancies			
Lymphoproliferative Syndromes (LPS)				
BRISTOL-MYERS SQUIBB CELGENE	Frontline			
ORIGIMED™ & CELGENE & BRISTOL-MYERS SQUIBB CELGENE	Lower Risk			
	Post DNA Failure			
Myelo/Lymphoid Leukemia (MLL)				
BMS2020™ (BRISTOL-MYERS SQUIBB CELGENE)	Relapsed/Refractory with an DNA Mutation			
	1st line with an DNA Mutation			
ASPTT/ SELINAX CD-MRMN	Relapsed/Refractory			
Lymphoma				
GI-MAGE™ Probody®	Relapsed T-cell Lymphoma 1st line			
BRIGHTGEN™ Mitvin	Diffuse Large B-cell Lymphoma Transplant-Eligible 1st line			
	Diffuse Large B-cell Lymphoma Transplant-non Eligible 1st line			
	Chronic Lymphocytic Leukemia 1st line			
	Follicular Lymphoma / Marginal Zone Lymphoma 1st line			
	Relapsed/ Refractory B-cell non-Lymphoblastic Lymphoma 1st line			
	Primary CNS Lymphoma 1st line			
	High Grade B-cell Lymphoma 1st line			
	Mantle Cell Lymphoma 1st line			
ORIGIMED™ (Lymphoma Indents)	Angioimunoblastic T-cell Lymphoma			
ORIGIMED™ & CELGENE	Refractory Hodgkin Lymphoma			
	Pediatric Hodgkin Lymphoma			
	Non-Hodgkin Lymphoma Diffuse Large B-cell Lymphoma			
	Non-Hodgkin Lymphoma Follicular Lymphoma			
	Primary Mediastinal Lymphoma			
MT Cetuximab (CC-90275)	Non-Hodgkin Lymphoma			
CD (ZILINA) (CC-99282)	Relapsed/Refractory Non-Hodgkin Lymphoma			
Anti-DDR1a	Non-Hodgkin Lymphoma			
LSD1 Cetuximab	Relapsed/Refractory Non-Hodgkin Lymphoma			
CD-MAGE-T	Relapsed/Refractory Non-Hodgkin Lymphoma			
Iberdomide	Non-Hodgkin Lymphoma			
ZNF217/CD	Non-Hodgkin Lymphoma			
Immunomodulation				
BRISTOL-MYERS SQUIBB CELGENE	Non-Transfusion-Dependent			
Immunology (IM)				
BMS2020™ (BRISTOL-MYERS SQUIBB CELGENE)	Processing Variant with Nucelmab			
BRISTOL-MYERS SQUIBB CELGENE	IgE Anemia			
Dermatology				
deucravacitinib	Psoriasis			
	Psoriatic Arthritis			
	Lupus Nephritis			
	Systemic Lupus Erythematosus			
	Crohn's Disease			
	Ulcerative Colitis			
	Discoid Lupus Erythematosus			
Iberdomide	Systemic Lupus Erythematosus			
cendakimab	Eosinophilic Esophagitis			
	Atopic Dermatitis			
Iberdomide/CC	Rheumatoid Arthritis			
	Systemic Lupus Erythematosus			
	Sjögren's Syndrome			
	Atopic Dermatitis			
FYN2 Cetuximab	Autoimmune Disease			
ofnelumab (TLR 7/8 Inhibitor)	Systemic Lupus Erythematosus			
	Cutaneous Lupus Erythematosus			
CYP8 Cetuximab	Atopic Dermatitis			
MC2 Cetuximab	Sclerosing Cholangitis			
IL-22/IL-18	Autoimmune Disease			
Anti-ZEAB	Autoimmune Disease			
ORIGIMED™ & CELGENE	Crohn's Disease			
Fibrotic Disease				

NME	Fibrosis	
HSP47✦	Non-alcoholic Steatohepatitis	
LPA_1 Antagonist	Pulmonary Fibrosis	
Cardiovascular		
ELIQUIS® (apixaban)	Pediatric Heart Disease	
	VTE prevention in pediatrics with ALL	
milvexian (FXIa Inhibitor)✦	Thrombotic Disorders	
FA-Relaxin	Heart Failure	
FXIa Inhibitor✦	Thrombotic Disorders	
mavacamten∆	Obstructive Hypertrophic Cardiomyopathy	
	Obstructive Hypertrophic Cardiomyopathy Septal Reduction Therapy eligible	
	Non-obstructive Hypertrophic Cardiomyopathy	
	Heart Failure with Preserved Ejection Fraction	
danicamtiv∆	Genetic Dilated Cardiomyopathy	
Cardiac Myosin Inhibitor∆	Hypertrophic Cardiomyopathy	
ROMK Inhibitor	Heart Failure	
Neuroscience		
FAAH/MGLL Dual Inhibitor	Neuroscience	
Anti-Tau✦ (Prothena)	Neuroscience	
BTK Inhibitor	Neuroscience	
eIF2b Activator✦ (Evotec)	Neuroscience	
Covid-19		
SARS-CoV-2 mAb Duo#✦	COVID-19 therapy or prevention	
ORENCIA® (abatacept)	COVID-19 treatment	

Please click on product name to see the Full U.S. Prescribing Information for OPDIVO®, YERVOY®, POMALYST®, EMPLICITI®, IDHIFA®, ISTODAX®, ORENCIA®, NULOJIX®, ELIQUIS®, REVLIMID®, REBLOZYL®, including **Boxed WARNINGS** for ELIQUIS®, REVLIMID®, POMALYST® and **Boxed WARNING** for YERVOY® **regarding immune-mediated adverse reactions** and IDHIFA® **regarding differentiation syndrome and** INREBIC® **regarding encephalopathy including Wernicke's.**

✦ Development Partnership: **OPDIVO**, **YERVOY**, **relatlimab**: Ono (our collaboration with Ono also includes other early stage compounds); **EMPLICITI**: AbbVie; **bempegaldesleukin**: Nektar; **cabozantinib**: Exelixis; **ELIQUIS**: Pfizer; **milvexian**: Janssen; **HSP47**: Nitto Denko; **CD3xPSCA**; **ABECMA** (**ide-cel**): bluebird bio; **REBLOZYL**: Acceleron Pharma, **IDHIFA**: Agios Pharmaceuticals, Inc.; **AHR**: Ikena Oncology; **CD22 ADC**: TriPhase Accelerator; **SARS-CoV-2 mAb Duo**: Rockefeller University; **TIGIT Bispecific**: Agenus; **farletuzumab-eribulin ADC**: Eisai; **rHuPH20**: Halozyme Therapeutics; **Anti-Tau**: Prothena; **eIF2b Activator**: Evotec ; **MAGE A4/8 TCE**: Immatics

∆ MyoKardia assets
^ Trial(s) exploring various combinations
# Partner-run study
◊ Product is marketed as IMNOVID® in the EU
+ Idecabtagene vicleucel
* Lisocabtagene maraleucel
NSCLC = Non-Small Cell Lung Cancer
SCLC = Small Cell Lung Cancer
SCCHN = Squamous Cell Carcinoma of the Head & Neck
HMA = Hypomethylating Agent
TCE = T-Cell Engager
ADC = Antibody Drug Conjugate
ESA = Erythropoiesis-Stimulating Agent

For information on approved uses, refer to approved product labeling.Phase I - clinical trials investigating safety of an investigational medicine in a small number of human subjects. Phase II - clinical trials investigating dosing, safety and efficacy of an investigational medicine in a small number of patients who have the disease or condition under study.Phase III - clinical trials investigating the safety and efficacy of an investigational medicine in a larger number of patients who have the disease or condition under study. For purposes of this chart, this includes the regulatory approval process prior to receiving marketing approval in the first major market.

© 2022 Bristol-Myers Squibb Company